相关实验视频

Updated: Jan 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

基于片段的发现,动态模拟和药理学研究的2-amino-pyrimidine衍生物作为HIPK2抑制剂

Yan Wu¹, Xinlan Hu¹, Songkai Wang²

¹Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China; Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Changsha, 410013, Hunan, China; Hunan Key Laboratory of Organ Fibrosis, Changsha, 410013, Hunan, China.

Chemico-biological interactions

|October 11, 2025

概括

一种新型药物,Hit 2c,有效地抑制家庭主体相互作用蛋白激酶2 (HIPK2),这是慢性病 (CKD) 纤维化和炎症的关键因素. 这种化合物显示出作为开发新CKD治疗方法的治疗的前景.

科学领域:

药理学和药物发现
腎臟病學 (nephrology) 是一種醫學專業.
分子生物学分子生物学

背景情况:

慢性病 (CKD) 是一种全球性健康问题,其特点是纤维化和炎症.
家庭主体相互作用蛋白激酶2 (HIPK2) 被确定为这些病理过程中的关键调节器.
对于治疗CKD有效的HIPK2抑制剂存在重大需求.

研究的目的:

使用基于碎片的药物发现 (FBDD) 方法开发一种新的HIPK2抑制剂.
为了评估开发的抑制剂的抗纤维和抗炎疗效,Hit 2c,在体外和体内.
阐明Hit 2c对HIPK2通路的结合机制和下游影响.

主要方法:

采用基于片段的药物发现 (FBDD) 来识别和优化Hit 2c.
利用分子对接,分子动力学模拟和雨采样来分析Hit 2c与HIPK2.2的结合.
通过测量细胞系中HIPK2下游途径和纤维化标志物的抑制来评估体外疗效 (NRK-49F,HK-2).
在腺因诱导的小鼠CKD模型中评估体内疗效,并进行药理动力学和药理动力学分析.

主要成果:

击中2c证明了强大的HIPK2激酶抑制 (IC50 = 0.20μM) 和抗增殖作用.
分子模拟显示了Hit 2c与HIPK2的稳定结合模式,通过与Lys288.8的关键键键稳定结合.
在体外,Hit 2c有效抑制了HIPK2下游通路,并降低了纤维化和炎症标志物.
在体内,Hit 2c治疗在小鼠CKD模型中减轻了损伤和纤维化,显示出与达帕格利弗洛辛相似的效果.
药理动力学分析显示半衰期为4.74小时,但口服生物利用率低 (3.92%),表明潜在的第一通代谢.

结论:

希特2c是一种新的HIPK2抑制剂支架,具有显著的体外和体外抗纤维和抗炎活性.
该化合物的稳定结合HIPK2,由关键的键驱动,是其抑制潜力的基础.
希特2c作为一个有前途的化合物,用于开发针对慢性脏病的向治疗方法.

关键词:

这就是HIPK2的原因.激酶抑制剂激酶抑制剂分子动力学模拟的模拟.皮里米丁衍生物的皮里米丁衍生物.患有脏纤维化

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...